Belantamab mafodotin for kidney failure, chronic

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 1 trial. Early trial in people, checking safety. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 21 May 2020: Trial registered, NCT04398745
  2. 9 Oct 2020: Trial started, NCT04398745

The trials

NCT04398745: A Study of Belantamab Mafodotin Monotherapy in Multiple Myeloma Participants With Normal and Varying Degree of Impaired Renal Function

State
Under way
Phase
Phase 1
People
36 taking part
Started
9 Oct 2020
Primary completion
21 Apr 2025
Arms
Part 1: Participants with normal/mild impaired renal function, Part 1: Participants with severe renal impairment, Part 2: Participants with ESRD (not on dialysis), Part 2: Participants with ESRD (on hemodialysis)
Results
Posted on the registry
  1. 21 May 2020: Trial registered
  2. 9 Oct 2020: Trial started
  3. 1 Jul 2026: Trial results posted

How the status changed

  1. 19 Nov 2026: First set: Phase 1 trial

About the treatment

Kind of treatment: Drug.

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.